EUVIMEDEUVIMED entdecken
Crossref

NEW ORAL ANTICOAGULANTS (NOACS) ARE THE GOLD STANDARD IN VENOUS THROMBOEMBOLISM

Luís Antunes

Portuguese Journal of Cardiac Thoracic and Vascular Surgery · 23.04.2021

DOI: 10.48729/pjctvs.73 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Portuguese Journal of Cardiac Thoracic and Vascular Surgery, erschienen am 23.04.2021. Verfasst von Luís Antunes.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Venous Thromboembolism (VTE) is an important cause of morbidity and mortality. The risk of recurrence could be very high without thromboprophylaxis. New oral anticoagulants (NOACs or DOACs) represent a new step in anticoagulation. Material and Methods: We searched for papers with trials, systematic reviews and meta-analysis involving NOACs in the treatment and secondary prevention of VTE. We also searched for guidelines of two medical societies (American College of Chest Physicians and International Society of Thrombosis and Haemostasis - ISTH).

Results

Six RCT (randomized controlled trial) comparing NOACs with Warfarin shew a non-inferiority in relation with recurrent VTE and major bleeding. Two RCT (SELECT-D and Hokusay cancer) and one meta-analysis shew low recurrence rate of VTE in cancer patients and higher rate of bleeding, mainly in gastrointestinal and genitourinary cancers. There are two RCTs involving NOACs in treatment of patients with Antiphospholipid Syndrome (APS).

Discussion

NOACs shew non-inferiority over AVK. Guidelines of CHEST 2016 recommend NOACs for VTE treatment in no cancer patients, and Low Molecular Weight Heparin (LMWH) for cancer patients. ISTH suggest NOACs as the first option in VTE cancer patients with low risk of bleeding. A recent RCT shews no benefit and increased risk of vascular events in APS patients treated with NOACs. NOACs are the gold standard for VTE treatment and secondary prevention in no cancer patients. They could be the first option in cancer patients with low risk of bleeding.

Schlagwörter

direct oral anticoagulantsvenous thromboembolismanticoagulationwarfarincancer-associated thrombosisantiphospholipid syndromebleeding riskrecurrence preventionlow molecular weight heparinclinical guidelines

Zitieren

APA

Antunes, L. (2021). NEW ORAL ANTICOAGULANTS (NOACS) ARE THE GOLD STANDARD IN VENOUS THROMBOEMBOLISM. Portuguese Journal of Cardiac Thoracic and Vascular Surgery. https://doi.org/10.48729/pjctvs.73

Vancouver

Antunes L. NEW ORAL ANTICOAGULANTS (NOACS) ARE THE GOLD STANDARD IN VENOUS THROMBOEMBOLISM. Portuguese Journal of Cardiac Thoracic and Vascular Surgery. 2021. doi:10.48729/pjctvs.73

BibTeX
@article{Antunes2021,
  author = {Antunes, Luís},
  title = {NEW ORAL ANTICOAGULANTS (NOACS) ARE THE GOLD STANDARD IN VENOUS THROMBOEMBOLISM},
  journal = {Portuguese Journal of Cardiac Thoracic and Vascular Surgery},
  year = {2021},
  doi = {10.48729/pjctvs.73}
}
Kostenlos starten →